Q: Innoviva has a low price to earnings of 6x times and plus 20 per cent roi in a growth industry and is funded by Glaxo. Can you explain the low valuation and is it a buy at these levels. Thank you
You can view 3 more answers this month. Sign up for a free trial for unlimited access.
Investment Q&A
Not investment advice or solicitation to buy/sell securities. Do your own due diligence and/or consult an advisor.
